The Future of Anti-Amyloid Trials
P S Aisen1, J Cummings, R Doody
1P.S. Aisen, University of Southern California Alzheimer's Therapeutic Research Institute, San Diego, CA, USA, paisen@usc.edu.
Abstract:
The termination of many clinical trials of amyloid-targeting therapies for the treatment of Alzheimer's disease (AD) has had a major impact on the AD clinical research enterprise. However, positive signals in recent studies have reinvigorated support for the amyloid hypothesis and amyloid-targeting strategies. In December 2019, the EU-US Clinical Trials on Alzheimer's Disease (CTAD) Task Force met to share learnings from these studies in order to inform future trials and promote the development of effective AD treatments. Critical factors that have emerged in studies of anti-amyloid monoclonal antibody therapies include developing a better understanding of the specific amyloid species targeted by different antibodies, advancing our insight into the mechanism by which those antibodies may reduce pathology, implementing more comprehensive repertoires of biomarkers into trials, and identifying appropriate doses. Studies suggest that Amyloid-Related Imaging Abnormalities - effusion type (ARIA-E) are a manageable safety concern and that caution should be exercised before terminating studies based on interim analyses. The Task Force concluded that opportunities for developing effective treatments include developing new biomarkers, intervening in early stages of disease, and use of combination therapies.
Insights
Recent Alzheimer's disease (AD) trial terminations were impactful, but positive signals for amyloid-targeting therapies are encouraging. Future AD drug development requires better biomarker understanding and early intervention strategies.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Research
Background:
- Alzheimer's disease (AD) drug development faces challenges, with numerous clinical trial terminations for amyloid-targeting therapies.
- Despite setbacks, recent positive findings have renewed interest in the amyloid hypothesis and related treatment strategies.
Purpose of the Study:
- To convene the EU-US Clinical Trials on Alzheimer's Disease (CTAD) Task Force to discuss learnings from recent AD trials.
- To identify critical factors for improving future Alzheimer's disease clinical trials and treatment development.
Main Methods:
- Discussion and knowledge sharing among experts at the CTAD Task Force meeting.
- Review of data from anti-amyloid monoclonal antibody therapies in Alzheimer's disease clinical trials.
Main Results:
- Key factors for successful trials include understanding specific amyloid targets, antibody mechanisms, comprehensive biomarkers, and optimal dosing.
- Amyloid-Related Imaging Abnormalities - effusion type (ARIA-E) are manageable, and interim analyses should be approached with caution.
Conclusions:
- Future Alzheimer's disease treatment development opportunities lie in novel biomarkers, early disease intervention, and combination therapies.
- Continued research and strategic trial design are crucial for advancing effective Alzheimer's disease therapies.
More Related Videos
Related Concept Videos
01:22Alzheimer's Disease: Treatment
03:03Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
03:03Amyloid Fibrils
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
01:26Atherosclerosis III: Management